Understanding the Brain

Acute disseminated encephalomyelitis

From Cognopedia
Jump to: navigation, search
Acute disseminated encephalomyelitis
Classification and external resources
ICD-10 G04.0
ICD-9 323.61
DiseasesDB 158
eMedicine neuro/500
MeSH D004673

Acute disseminated encephalomyelitis (ADEM) is an immune mediated disease of the brain.[1][2][3] It usually occurs following a viral infection but may appear following vaccination, bacterial or parasitic infection, or even appear spontaneously. As it involves autoimmune demyelination, it is similar to multiple sclerosis, and is considered part of the Multiple sclerosis borderline[4][5] diseases. The incidence rate is about 8 per 1,000,000 people per year.[6] Although it occurs in all ages, most reported cases are in children and adolescents, with the average age around 5 to 8 years old.[7][8][9] The mortality rate may be as high as 5%, full recovery is seen in 50 to 75% of cases, while up to 70 to 90% recover with some minor residual disability.[10] The average time to recover is one to six months.

ADEM produces multiple inflammatory lesions in the brain and spinal cord, particularly in the white matter. Usually these are found in the subcortical and central white matter and cortical gray-white junction of both cerebral hemispheres, cerebellum, brainstem, and spinal cord,[11] but periventricular white matter and gray matter of the cortex, thalami and basal ganglia may also be involved.

When the patient suffers more than one demyelinating episode, it is called Recurrent disseminated encephalomyelitis[12] or Multiphasic disseminated encephalomyelitis[13](MDEM).

Causes and antecedent history

Viral infections thought to induce ADEM include influenza virus, enterovirus, measles, mumps, rubella, varicella zoster, Epstein Barr virus, cytomegalovirus, herpes simplex virus, hepatitis A, and coxsackievirus; while the bacterial infections include Mycoplasma pneumoniae, Borrelia burgdorferi, Leptospira, and beta-hemolytic Streptococci.[14] The only vaccine proven to induce ADEM is the Semple form of the rabies vaccine, but hepatitis B, pertussis, diphtheria, measles, mumps, rubella, pneumococcus, varicella, influenza, Japanese encephalitis, and polio vaccines have all been implicated.[6][15][16][17][18][19][20][21][22][23][24] In rare cases, ADEM seems to follow from organ transplantation.[18] The risk of ADEM from measles vaccination is about 1 to 2 per million,[17] which is far lower than the risk of developing ADEM from an actual measles infection, which is about 1 per 1000 for measles (and 1 per 5000 for rubella).[19][25] Measles infection also appears to lead to worse ADEM outcomes than cases associated with measles immunization. Some vaccines, later shown to have been contaminated with host animal CNS tissue, have ADEM incident rates as high as 1 in 600.[15]


ADEM has an abrupt onset and a monophasic course. Symptoms usually begin 1–3 weeks after infection or vaccination. Major symptoms include fever, headache, drowsiness, seizures and coma. Although initially the symptoms are usually mild, they worsen rapidly over the course of hours to days, with the average time to maximum severity being about four and a half days.[18] Additional symptoms include hemiparesis, paraparesis, and cranial nerve palsies.[26]


No controlled clinical trials have been conducted on ADEM treatment, but aggressive treatment aimed at rapidly reducing inflammation of the CNS is standard. The widely accepted first-line treatment is high doses of intravenous corticosteroids,[27] such as methylprednisolone or dexamethasone, followed by 3–6 weeks of gradually lower oral doses of prednisolone. Patients treated with methylprednisolone have shown better outcomes than those treated with dexamethasone.[18] Oral tapers of less than three weeks duration show a higher chance of relapsing,[8][13] and tend to show poorer outcomes. Other antiinflamatory and immunosuppressive therapies have been reported to show beneficial effect, such as plasmapheresis, high doses of intravenous immunoglobulin (IVIg),[27][28] mitoxantrone and cyclophosphamide. These are considered alternative therapies, used when corticosteroids cannot be used, or fail to show an effect.

There is some evidence to suggest that patients may respond to a combination of methylprednisolone and immunoglobulins if they fail to respond to either separately[29] In a study of 16 children with ADEM, 10 recovered completely after high-dose methylprednisolone, one severe case that failed to respond to steroids recovered completely after IVIg; the five most severe cases -with ADAM and severe peripheral neuropathy- were treated with combined high-dose methylprednisolone and immunoglobulin, two remained paraplegic, one had motor and cognitive handicaps, and two recovered.[27] A recent review of IVIg treatment of ADEM (of which the previous study formed the bulk of the cases) found that 70% of children showed complete recovery after treatment with IVIg, or IVIg plus corticosteroids.[30] A study of IVIg treatment in adults with ADEM showed that IVIg seems more effective in treating sensory and motor disturbances, while steroids seem more effective in treating impairments of cognition, consciousness and rigor.[28] This same study found one subject, a 71-year-old man who had not responded to steroids, that responded to a IVIg treatment 58 days after disease onset.


Full recovery is seen in 50 to 70% of cases, ranging to 70 to 90% recovery with some minor residual disability (typically assessed using measures such as mRS or EDSS), average time to recover is one to six months.[10] The mortality rate may be as high as 5%.[10] Poorer outcomes are associated with unresponsiveness to steroid therapy, unusually severe neurological symptoms, or sudden onset. Children tend to have more favorable outcomes than adults, and cases presenting without fevers tend to have poorer outcomes.[31] The latter effect may be due to either protective effects of fever, or that diagnosis and treatment is sought more rapidly when fever is present.

Motor deficits

Residual motor deficits are estimated to remain in about 8 to 30% of cases, the range in severity from mild clumsiness to ataxia and hemiparesis.[14]


Patients with demyelinating illnesses, such as MS, have shown cognitive deficits even when there is minimal physical disability.[32] Research suggests that similar effects are seen after ADEM, but that the deficits are less severe than those seen in MS. A study of six children with ADEM (mean age at presentation 7.7 years) were tested for a range of neurocognitive tests after an average of 3.5 years of recovery.[33] All six children performed in the normal range on most tests, including verbal IQ and performance IQ, but performed at least one standard deviation below age norms in at least one cognitive domain, such as complex attention (one child), short-term memory (one child) and internalizing behaviour/affect (two children). Group means for each cognitive domain were all within one standard deviation of age norms, demonstrating that, as a group, they were normal. These deficits were less severe than those seen in similar aged children with a diagnosis of MS.[34]

Another study compared nineteen children with a history of ADEM, of which 10 were five years of age or younger at the time (average age 3.8 years old, tested an average of 3.9 years later) and nine were older (mean age 7.7y at time of ADEM, tested an average of 2.2 years later) to nineteen matched controls.[35] Scores on IQ tests and educational achievement were lower for the young onset ADEM group (average IQ 90) compared to the late onset (average IQ 100) and control groups (average IQ 106), while the late onset ADEM children scored lower on verbal processing speed. Again, all groups means were within one standard deviation of the controls, meaning that while effects were statistically reliable, the children were as a whole, still within the normal range. There were also more behavioural problems in the early onset group, although there is some suggestion that this may be due, at least in part, to the stress of hospitalization at a young age.[36][37]

ADEM and multiple sclerosis

While ADEM and MS both involve autoimmune demyelination, they differ in many clinical, genetic, imaging, and histopathological aspects.[38] Some authors consider MS and its borderline forms to constitute a spectrum, differing only in chronicity, severity, and clinical course,[39][40] while others consider them discretely different diseases.[5]

Problems for differential diagnosis increase due to the lack of agreement for a definition of Multiple Sclerosis.[41] For some people MS should be considered a clinical entity based in inflammatory lesions separated in time and space.[42] As some cases of ADEM satisfy these conditions, they should be considered inside the MS spectrum. Using a pathological definition instead, they would be apart (plaques in the white matter in MS are sharply delineated, while the inflammation in ADEM is widely disseminated and ill-defined).

Acute hemorrhagic leukoencephalitis

Acute hemorrhagic leukoencephalitis (AHL, or AHLE), also known as acute necrotizing encephalopathy (ANE), acute hemorrhagic encephalomyelitis (AHEM), acute necrotizing hemorrhagic leukoencephalitis (ANHLE), Weston-Hurst syndrome, or Hurst's disease, is a hyperacute and frequently fatal form of ADEM. AHL is relatively rare (less than 100 cases have been reported in the medical literature as of 2006),[43] it is seen in about 2% of ADEM cases,[18] and is characterized by necrotizing vasculitis of venules and hemorrhage, and edema.[44] Death is common in the first week[45] and overall mortality is about 70%,[43] but increasing evidence points to favorable outcomes after aggressive treatment with corticosteroids, immunoglobulins, cyclophosphamide, and plasma exchange.[14] About 70% of survivors show residual neurological deficits,[44] but some survivors have shown surprisingly little deficit considering the magnitude of the white matter affected.[45] This disease has been occasionally associated with ulcerative colitis and Crohn's disease, septicemia associated with immune complex deposition, methanol poisoning, and other underlying conditions.

Experimental allergic encephalomyelitis

Experimental allergic encephalomyelitis (EAE) is an animal model of CNS inflammation and demyelination frequently used to investigate potential MS treatments.[46] An acute monophasic illness, EAE is far more similar to ADEM than MS.[47]

See also


  1. Dale RC (April 2003). "Acute disseminated encephalomyelitis". Semin Pediatr Infect Dis 14 (2): 90–5. doi:10.1053/spid.2003.127225. PMID 12881796. 
  2. Garg RK (January 2003). "Acute disseminated encephalomyelitis". Postgrad Med J 79 (927): 11–7. doi:10.1136/pmj.79.927.11. PMC 1742586. PMID 12566545. http://pmj.bmj.com/cgi/pmidlookup?view=long&pmid=12566545. 
  3. Jones CT (November 2003). "Childhood autoimmune neurologic diseases of the central nervous system". Neurol Clin 21 (4): 745–64. doi:10.1016/S0733-8619(03)00007-0. PMID 14743647. 
  4. Rust RS (June 2000). "Multiple sclerosis, acute disseminated encephalomyelitis, and related conditions". Semin Pediatr Neurol 7 (2): 66–90. doi:10.1053/pb.2000.6693. PMID 10914409. 
  5. 5.0 5.1 Poser CM, Brinar VV (October 2007). "Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review". Acta Neurol. Scand. 116 (4): 201–6. doi:10.1111/j.1600-0404.2007.00902.x. PMID 17824894. 
  6. 6.0 6.1 Leake JA, Albani S, Kao AS, et al. (August 2004). "Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features". Pediatr. Infect. Dis. J. 23 (8): 756–64. doi:10.1097/01.inf.0000133048.75452.dd. PMID 15295226. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0891-3668&volume=23&issue=8&spage=756. 
  7. Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ (May 2001). "Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children". Neurology 56 (10): 1308–12. PMID 11376179. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11376179. 
  8. 8.0 8.1 Anlar B, Basaran C, Kose G, et al. (August 2003). "Acute disseminated encephalomyelitis in children: outcome and prognosis". Neuropediatrics 34 (4): 194–9. doi:10.1055/s-2003-42208. PMID 12973660. 
  9. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (May 2001). "Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients". Neurology 56 (10): 1313–8. PMID 11376180. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11376180. 
  10. 10.0 10.1 10.2 Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O (June 2007). "Acute disseminated encephalomyelitis: an acute hit against the brain". Curr. Opin. Neurol. 20 (3): 247–54. doi:10.1097/WCO.0b013e3280f31b45. PMID 17495616. 
  11. Wingerchuk DM (May 2003). "Postinfectious encephalomyelitis". Curr Neurol Neurosci Rep 3 (3): 256–64. doi:10.1007/s11910-003-0086-x. PMID 12691631. 
  12. Poser CM (May 2008). "Multiple sclerosis and recurrent disseminated encephalomyelitis are different diseases". Arch. Neurol. 65 (5): 674; author reply 674–5. doi:10.1001/archneur.65.5.674-a. PMID 18474749. 
  13. 13.0 13.1 Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG (December 2000). "Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children". Brain 123 Pt 12 (12): 2407–22. doi:10.1093/brain/123.12.2407. PMID 11099444. http://brain.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=11099444. 
  14. 14.0 14.1 14.2 Tenembaum S, Chitnis T, Ness J, Hahn JS (April 2007). "Acute disseminated encephalomyelitis". Neurology 68 (16 Suppl 2): S23–36. doi:10.1212/01.wnl.0000259404.51352.7f. PMID 17438235. 
  15. 15.0 15.1 Hemachudha T, Griffin DE, Giffels JJ, Johnson RT, Moser AB, Phanuphak P (February 1987). "Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination". N. Engl. J. Med. 316 (7): 369–74. doi:10.1056/NEJM198702123160703. PMID 2433582. 
  16. Hemachudha T, Griffin DE, Johnson RT, Giffels JJ (January 1988). "Immunologic studies of patients with chronic encephalitis induced by post-exposure Semple rabies vaccine". Neurology 38 (1): 42–4. PMID 2447520. 
  17. 17.0 17.1 Murthy JM (September 2002). "Acute disseminated encephalomyelitis". Neurol India 50 (3): 238–43. PMID 12391446. http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2002;volume=50;issue=3;spage=238;epage=43;aulast=Murthy. 
  18. 18.0 18.1 18.2 18.3 18.4 Tenembaum S, Chamoles N, Fejerman N (October 2002). "Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients". Neurology 59 (8): 1224–31. PMID 12391351. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12391351. 
  19. 19.0 19.1 Fenichel GM (August 1982). "Neurological complications of immunization". Ann. Neurol. 12 (2): 119–28. doi:10.1002/ana.410120202. PMID 6751212. 
  20. Takahashi H, Pool V, Tsai1 TF, Chen RT (July 2000). "Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group". Vaccine 18 (26): 2963–9. doi:10.1016/S0264-410X(00)00111-0. PMID 10825597. http://linkinghub.elsevier.com/retrieve/pii/S0264410X00001110. 
  21. Tourbah A, Gout O, Liblau R, et al. (July 1999). "Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?". Neurology 53 (2): 396–401. PMID 10430433. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=10430433. 
  22. Karaali-Savrun F, Altintaş A, Saip S, Siva A (November 2001). "Hepatitis B vaccine related-myelitis?". Eur. J. Neurol. 8 (6): 711–5. doi:10.1046/j.1468-1331.2001.00290.x. PMID 11784358. http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1351-5101&date=2001&volume=8&issue=6&spage=711. 
  23. Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM (December 2005). "Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004". JAMA 294 (21): 2744–50. doi:10.1001/jama.294.21.2744. PMID 16333010. 
  24. Ozawa H, Noma S, Yoshida Y, Sekine H, Hashimoto T (August 2000). "Acute disseminated encephalomyelitis associated with poliomyelitis vaccine". Pediatr. Neurol. 23 (2): 177–9. doi:10.1016/S0887-8994(00)00167-3. PMID 11020647. http://linkinghub.elsevier.com/retrieve/pii/S0887-8994(00)00167-3. 
  25. Miller HG, Stanton JB, Gibbons JL (1956). "Parainfectious encephalomyelitis and related syndromes". Quarterly Journal of Medicine 25 (100): 427–505. PMID 13379602. 
  26. Allmendinger A, Krauthamer A, Spektor V. Case of the month. Diagnostic Imaging. 2009;31(12):10.
  27. 27.0 27.1 27.2 Shahar E, Andraus J, Savitzki D, Pilar G, Zelnik N (November 2002). "Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins". J. Child Neurol. 17 (11): 810–4. doi:10.1177/08830738020170111001. PMID 12585719. 
  28. 28.0 28.1 Ravaglia S, Piccolo G, Ceroni M, et al. (November 2007). "Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg". J. Neurol. 254 (11): 1518–23. doi:10.1007/s00415-007-0561-4. PMID 17965959. 
  29. Straussberg R, Schonfeld T, Weitz R, Karmazyn B, Harel L (February 2001). "Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins". Pediatr. Neurol. 24 (2): 139–43. doi:10.1016/S0887-8994(00)00229-0. PMID 11275464. http://linkinghub.elsevier.com/retrieve/pii/S0887-8994(00)00229-0. 
  30. Feasby T, Banwell B, Benstead T, et al. (April 2007). "Guidelines on the use of intravenous immune globulin for neurologic conditions". Transfus Med Rev 21 (2 Suppl 1): S57–107. doi:10.1016/j.tmrv.2007.01.002. PMID 17397768. 
  31. Lin CH, Jeng JS, Hsieh ST, Yip PK, Wu RM (February 2007). "Acute disseminated encephalomyelitis: a follow-up study in Taiwan". J. Neurol. Neurosurg. Psychiatr. 78 (2): 162–7. doi:10.1136/jnnp.2005.084194. PMC 2077670. PMID 17028121. 
  32. Foong J, Rozewicz L, Quaghebeur G, et al. (January 1997). "Executive function in multiple sclerosis. The role of frontal lobe pathology". Brain 120 (Pt 1): 15–26. doi:10.1093/brain/120.1.15. PMID 9055794. http://brain.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9055794. 
  33. Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR (August 2003). "Neurocognitive outcome after acute disseminated encephalomyelitis". Pediatr. Neurol. 29 (2): 117–23. doi:10.1016/S0887-8994(03)00143-7. PMID 14580654. http://linkinghub.elsevier.com/retrieve/pii/S0887899403001437. 
  34. Banwell BL, Anderson PE (March 2005). "The cognitive burden of multiple sclerosis in children". Neurology 64 (5): 891–4. doi:10.1212/01.WNL.0000152896.35341.51 (inactive 2008-08-27). PMID 15753431. 
  35. Jacobs RK, Anderson VA, Neale JL, Shield LK, Kornberg AJ (September 2004). "Neuropsychological outcome after acute disseminated encephalomyelitis: impact of age at illness onset". Pediatr. Neurol. 31 (3): 191–7. doi:10.1016/j.pediatrneurol.2004.03.008. PMID 15351018. 
  36. Douglas JW (August 1975). "Early hospital admissions and later disturbances of behaviour and learning". Dev Med Child Neurol 17 (4): 456–80. doi:10.1111/j.1469-8749.1975.tb03497.x. PMID 1158052. 
  37. Daviss WB, Racusin R, Fleischer A, Mooney D, Ford JD, McHugo GJ (May 2000). "Acute stress disorder symptomatology during hospitalization for pediatric injury". J Am Acad Child Adolesc Psychiatry 39 (5): 569–75. doi:10.1097/00004583-200005000-00010. PMID 10802974. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0890-8567&volume=39&issue=5&spage=569. 
  38. Wingerchuk DM, Lucchinetti CF (June 2007). "Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis". Curr. Opin. Neurol. 20 (3): 343–50. doi:10.1097/WCO.0b013e3280be58d8. PMID 17495631. 
  39. Weinshenker B, Miller D. (1999). Multiple sclerosis: one disease or many? In: Siva A, Kesselring J, Thompson A, eds. Frontiers in multiple sclerosis. London: Dunitz, p37-46.
  40. Hartung HP, Grossman RI (May 2001). "ADEM: distinct disease or part of the MS spectrum?". Neurology 56 (10): 1257–60. PMID 11376169. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11376169. 
  41. H. Lassmann, Acute disseminated encephalomyelitis and multiple sclerosis, doi: 10.1093/brain/awp342, [1]
  42. McDonald WI, Compston A, Edan G, et al. (2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis [2]". Ann. Neurol. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. 
  43. 43.0 43.1 Davies NW, Sharief MK, Howard RS (July 2006). "Infection-associated encephalopathies: their investigation, diagnosis, and treatment". J. Neurol. 253 (7): 833–45. doi:10.1007/s00415-006-0092-4. PMID 16715200. 
  44. 44.0 44.1 Stone MJ, Hawkins CP (2007). "A medical overview of encephalitis". Neuropsychol Rehabil 17 (4–5): 429–49. doi:10.1080/09602010601069430. PMID 17676529. 
  45. 45.0 45.1 Archer H, Wall R (February 2003). "Acute haemorrhagic leukoencephalopathy: two case reports and review of the literature". J. Infect. 46 (2): 133–7. doi:10.1053/jinf.2002.1096. PMID 12634076. http://linkinghub.elsevier.com/retrieve/pii/S0163445302910960. 
  46. Rivers TM, Schwentker FF (1935). "Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys". J. Exp. Med. 61 (5): 689–701. doi:10.1084/jem.61.5.689. 
  47. Sriram S, Steiner I (December 2005). "Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis". Ann. Neurol. 58 (6): 939–45. doi:10.1002/ana.20743. PMID 16315280. 

External links

  1. REDIRECT Template:Office of Rare Diseases